Podcast: New Opportunities for Improved Patient Outcomes in Graft-Versus-Host-Disease

STATEMENT OF NEED

Graft-versus-host disease (GHVD) is a common complication of allogeneic hematopoietic stem cell transplant (HSCT) and a major contributor to morbidity and mortality (DeFilipp et al, 2021; Malard et al, 2020). Acute GVHD occurs within 100 days of transplant and typically targets the skin, gastrointestinal tract, and liver (LLS, 2022). Chronic GVHD often presents within the first year following HSCT but may develop in subsequent years. It most commonly affects the skin; however, involvement of other sites such as the liver, gastrointestinal tract, joints, fascia, and lungs can occur alone or concurrently (LLS, 2022). In recent years, advances in the management of other HSCT"related complications such as cytomegalovirus and invasive fungal infections have led to substantial reductions in mortality (Rahi et al, 2021). Despite intensive research, GVHD remains a challenge due to its heterogeneity and complex pathogenesis (Malard et al, 2020). In this podcast, Shernan Holtan, MD, of the University of Minnesota and Carrie Kitko, MD, of Vanderbilt University Medical Center will explore new biomarkers used for diagnosis and therapy selection, discuss the latest clinical trial findings, and advise practitioners on how to individualize treatment to patients’ needs.

TARGET AUDIENCE

Hematology/oncology physicians, nurse practitioners, physician associates, oncology nurses, and other health care professionals involved in the treatment of patients with graft-versus-host disease (GVHD).

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to

Appraise emerging insights into biomarkers for improved diagnosis and therapy selection in GVHD
Assess recent clinical trial findings on the efficacy and safety of emerging therapies for acute and chronic GVHD
Evaluate the implications of recent clinical advances in GVHD for supporting patients and meeting their individual care needs